biosimilars

News

Samsung Biologics scores $897 million CMO order with Pfizer

South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics marks another contract milestone as the company announces two high-value deals totalling £897

News

Biosimilar uptake remains poor, but Sandoz has a plan

Sandoz is a major player in biosimilar medicines, so it’s no surprise that it is concerned about how slowly these drugs are making inroads against their brand-name equival

Market Access

Has a biosimilar tipping point been achieved in the US?

As the biggest selling drug of all time begins to be hit by biosimilar competition, Ben Hargreaves asks whether biosimilars adoption could be about to take-off in the US.

News

Standalone Sandoz eyes $3bn in new product sales by 2028

Novartis’ generics unit Sandoz will tell investors today that it can add $3 billion in annual sales from the launch of new products, after it spins out of its parent compa

News

AbbVie’s growth drugs fail to offset Humira competition

Biosimilar competition to AbbVie’s cash-cow product Humira ramped up in the first quarter, but more worrying for the company was disappointing growth among the products it

News

Litigation costs pour cold water on J&J’s finances

Johnson & Johnson posted a loss in the first three months of the year as it booked a massive $6.9 billion charge related to its recently-agreed proposal to settle clai

Samsung Biologics scores $897 million CMO order with Pfizer

Biosimilar uptake remains poor, but Sandoz has a plan

Has a biosimilar tipping point been achieved in the US?

Standalone Sandoz eyes $3bn in new product sales by 2028

AbbVie’s growth drugs fail to offset Humira competition

Litigation costs pour cold water on J&J’s finances

Ambros' $125m for pain disorder drug, and other financings

How to meet your physicians where they are online

biosimilars

Editor's Picks